CO2023004435A2 - Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos - Google Patents
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenosInfo
- Publication number
- CO2023004435A2 CO2023004435A2 CONC2023/0004435A CO2023004435A CO2023004435A2 CO 2023004435 A2 CO2023004435 A2 CO 2023004435A2 CO 2023004435 A CO2023004435 A CO 2023004435A CO 2023004435 A2 CO2023004435 A2 CO 2023004435A2
- Authority
- CO
- Colombia
- Prior art keywords
- compound
- crystalline
- estrogen receptor
- amorphous forms
- polymorphic forms
- Prior art date
Links
- 230000015556 catabolic process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- TZZDVPMABRWKIZ-XMOGEVODSA-N (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-XMOGEVODSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se refiere a formas polimórficas de (S)-3-(5-(4-((1-(4-((1R,2S)-6-hidroxi-2-fenil-1,2,3,4-tetrahidronaftalen-1-il)fenil)piperidin-4-il)metil)piperazin-1-il)-1-oxoisoindolin-2- il)piperidina-2,6-diona, (Compuesto A), a los métodos de fabricación de estas formas polimórficas y a las composiciones que comprenden estas formas polimórficas. Estas formas polimórficas son útiles en el tratamiento de varias enfermedades, que incluyen, por ejemplo, cáncer de mama.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078225P | 2020-09-14 | 2020-09-14 | |
| PCT/US2021/050046 WO2022056368A1 (en) | 2020-09-14 | 2021-09-13 | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023004435A2 true CO2023004435A2 (es) | 2023-04-27 |
Family
ID=78080527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0004435A CO2023004435A2 (es) | 2020-09-14 | 2023-04-10 | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220081416A1 (es) |
| EP (1) | EP4211128A1 (es) |
| JP (1) | JP2023541434A (es) |
| KR (1) | KR20230069144A (es) |
| CN (1) | CN116390916A (es) |
| AR (1) | AR123492A1 (es) |
| AU (1) | AU2021342287A1 (es) |
| BR (1) | BR112023004656A2 (es) |
| CA (1) | CA3194954A1 (es) |
| CL (1) | CL2023000712A1 (es) |
| CO (1) | CO2023004435A2 (es) |
| CR (1) | CR20230162A (es) |
| DO (1) | DOP2023000052A (es) |
| EC (1) | ECSP23027481A (es) |
| IL (1) | IL301155A (es) |
| MX (1) | MX2023002979A (es) |
| PE (1) | PE20231555A1 (es) |
| RS (1) | RS20230288A1 (es) |
| TW (1) | TW202214236A (es) |
| WO (1) | WO2022056368A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117229286A (zh) * | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3689868T (lt) * | 2016-12-01 | 2023-12-27 | Arvinas Operations, Inc. | Tetrahidronaftaleno ir tetrahidroizochinolino dariniai kaip estrogenų receptorių destruktoriai |
-
2021
- 2021-09-13 AR ARP210102530A patent/AR123492A1/es unknown
- 2021-09-13 CN CN202180070126.4A patent/CN116390916A/zh active Pending
- 2021-09-13 PE PE2023001149A patent/PE20231555A1/es unknown
- 2021-09-13 MX MX2023002979A patent/MX2023002979A/es unknown
- 2021-09-13 EP EP21787193.8A patent/EP4211128A1/en active Pending
- 2021-09-13 CR CR20230162A patent/CR20230162A/es unknown
- 2021-09-13 KR KR1020237011950A patent/KR20230069144A/ko unknown
- 2021-09-13 US US17/472,847 patent/US20220081416A1/en active Pending
- 2021-09-13 RS RS20230288A patent/RS20230288A1/sr unknown
- 2021-09-13 CA CA3194954A patent/CA3194954A1/en active Pending
- 2021-09-13 WO PCT/US2021/050046 patent/WO2022056368A1/en active Application Filing
- 2021-09-13 TW TW110134024A patent/TW202214236A/zh unknown
- 2021-09-13 AU AU2021342287A patent/AU2021342287A1/en active Pending
- 2021-09-13 IL IL301155A patent/IL301155A/en unknown
- 2021-09-13 BR BR112023004656A patent/BR112023004656A2/pt unknown
- 2021-09-13 JP JP2023516491A patent/JP2023541434A/ja active Pending
-
2023
- 2023-03-13 CL CL2023000712A patent/CL2023000712A1/es unknown
- 2023-03-14 DO DO2023000052A patent/DOP2023000052A/es unknown
- 2023-04-10 CO CONC2023/0004435A patent/CO2023004435A2/es unknown
- 2023-04-14 EC ECSENADI202327481A patent/ECSP23027481A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS20230288A1 (sr) | 2023-06-30 |
| DOP2023000052A (es) | 2023-07-31 |
| AR123492A1 (es) | 2022-12-07 |
| IL301155A (en) | 2023-05-01 |
| MX2023002979A (es) | 2023-04-10 |
| CL2023000712A1 (es) | 2023-10-20 |
| JP2023541434A (ja) | 2023-10-02 |
| TW202214236A (zh) | 2022-04-16 |
| CR20230162A (es) | 2023-06-02 |
| US20220081416A1 (en) | 2022-03-17 |
| KR20230069144A (ko) | 2023-05-18 |
| CA3194954A1 (en) | 2022-03-17 |
| WO2022056368A1 (en) | 2022-03-17 |
| AU2021342287A1 (en) | 2023-04-13 |
| PE20231555A1 (es) | 2023-10-03 |
| BR112023004656A2 (pt) | 2023-05-09 |
| CN116390916A (zh) | 2023-07-04 |
| EP4211128A1 (en) | 2023-07-19 |
| ECSP23027481A (es) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22077299A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k | |
| AR057222A1 (es) | Agonistas del receptor del neuropeprtido -2 | |
| NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CL2021000566A1 (es) | Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589) | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| CO2023004435A2 (es) | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos | |
| CU23550B7 (es) | Derivados de pirrolo-pirazol sustituidos como inhibidores de quinasa | |
| AR051904A1 (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r) | |
| UY30292A1 (es) | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico | |
| PE20140171A1 (es) | Pirazoles fungicidas y sus mezclas | |
| CR11620A (es) | Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met | |
| PE20160521A1 (es) | Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida | |
| ECSP088120A (es) | Derivados de piridazinona como agonistas del receptorde la hormona tiroidea | |
| UY30640A1 (es) | Compuestos | |
| ECSP23083562A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
| CU20160183A7 (es) | Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| UY32574A (es) | Antagonistas del receptor cxcr3 | |
| UY28903A1 (es) | Nuevos derivados de piridazinona | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| UY30664A1 (es) | Derivados de benzacepin-2(ih)-ona | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| CL2023000074A1 (es) | Métodos para fabricar un compuesto bifuncional, formas del compuesto bifuncional y formas de dosificación |